FDA Approves Tregzi for Treatment of Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation by Madaline Spencer| Published on: Jul 14, 2026

FDA Approves Tregzi for Treatment of Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation by Madaline Spencer| Published on: Jul 14, 2026 The US Food and Drug Administration (FDA) has approved Orca-T (Tregzi), the first regulatory T cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). https://checkrare.com/fda-approves-tregzi-for-treatment-of-graft-versus-host-disease-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation/